Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Tuesday, June 14, 2011

FMO3 genetics lesson (part 2) : DNA, RNA and the protein

In this post we will familiarise you with the way a protein is made, in this case the FMO3 protein. The DNA has the coding for the amino acid sequence, that is transcripted into long RNA and then processed into short RNA, which is then converted into the final  sequence of amino acids that make up the  required protein (in this case the FMO3 protein).

Exons and Introns
DNA has the coding part on exons, which has the relevant information to make the FMO3 protein, but also contains introns which are currently a mystery and it is not known if they are needed. Some may regard introns as mostly junk DNA. Unfortunately, while introns seem to play no obvious role in building the protein, it seems likely that having mutants/variants amongst the introns  can still negatively affect the formation of the correct  full protein. This may explain why some people seem quite obvious genetic TMAU cases in the urine test, but the DNA test does not seem to show any mutantions. The DNA test usually only checks the coding region of the FMO3 DNA in the exons, and not the introns.

In FMO3, there are 9 exons, of which 8 (exon 2-8) are regarded as the coding parts. Probably most DNA tests will check these 8 coding regions specifically.

As can be seen from the slide above from Professor Shephard's slideshow (full video can be seen in the sidebar), The DNA is transcripted to long RNA and then processed into the short RNA form which does not contain the introns, and only contains the exons. It is now ready to code the amino acid sequence to build the FMO3 protein. The RNA is the part which has the sequence for the 532 amino acids needed to build FMO3 (the DNA coding being much longer including introns).

Looking at the terminology geneticists use, it can be seen that sometimes they refer to e.g. 668 (which obviously is higher than 532) because it is referring to a mutation/variant on the DNA strand (which is much longer), which corresponds with a fault at amino acid 223 (which means it is referring to the position on the final protein or short RNA of 532 amino acids).

It seems that nonsense mutations produce a 'false' stop to the production of the 532 amino acids. These make up about 5% of the known genetic TMAU mutations currently known.  The drug 'Ataluren' is hoping to be able to over-ride false stops in nonsense mutations and allow the full protein to be formed. The other FMO3 mutations/variants are mostly 'missense' mutations, where the wrong amino acid has been coded for a certain position in the 532.

A full overview of the genetics of FMO3 can be seen in the video given by Professor Shephard in the sidebar.

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online at no extra cost to you.
MEBO gets small commission from Amazon.

Use your credit card
to make your donation.

A EURORDIS and NORD Member Organization 


Post a Comment